4/23
11:08 am
azn
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect [Yahoo! Finance]
Low
Report
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect [Yahoo! Finance]
4/23
01:19 am
azn
BenevolentAI Provides an Update on Its Business Priorities [Yahoo! Finance]
Low
Report
BenevolentAI Provides an Update on Its Business Priorities [Yahoo! Finance]
4/22
10:56 am
azn
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics [Yahoo! Finance]
Low
Report
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics [Yahoo! Finance]
4/22
09:46 am
azn
With 85% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing [Yahoo! Finance]
Low
Report
With 85% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing [Yahoo! Finance]
4/22
05:45 am
azn
Vaccines Market worth $65.3 billion by 2028: BCC Research LLC [Yahoo! Finance]
Low
Report
Vaccines Market worth $65.3 billion by 2028: BCC Research LLC [Yahoo! Finance]
4/20
05:17 pm
azn
You may have inherited risks of developing cancer: Here's what you need to know [CBS News]
Low
Report
You may have inherited risks of developing cancer: Here's what you need to know [CBS News]
4/19
04:33 pm
azn
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024 [Yahoo! Finance]
Low
Report
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024 [Yahoo! Finance]
4/19
08:42 am
azn
United States Non-small Cell Lung Cancer Digital Marketing Analysis Report 2023: Merck's Keytruda.com Achieved the Highest Total Traffic, Followed by BMS's Opdivo.com and AstraZeneca's Imfinzi.com [Yahoo! Finance]
Low
Report
United States Non-small Cell Lung Cancer Digital Marketing Analysis Report 2023: Merck's Keytruda.com Achieved the Highest Total Traffic, Followed by BMS's Opdivo.com and AstraZeneca's Imfinzi.com [Yahoo! Finance]
4/19
08:42 am
azn
Prescient Healthcare Group Appoints Two New Members to its Board of Directors [Yahoo! Finance]
Low
Report
Prescient Healthcare Group Appoints Two New Members to its Board of Directors [Yahoo! Finance]
4/19
07:32 am
azn
Eosinophilic Esophagitis Pipeline Research 2024 [Yahoo! Finance]
Low
Report
Eosinophilic Esophagitis Pipeline Research 2024 [Yahoo! Finance]
4/19
03:09 am
azn
For my beloved family, I leave you my.....fridge freezer! New research from Beko reveals the strangest items that are passed on [Yahoo! Finance]
Low
Report
For my beloved family, I leave you my.....fridge freezer! New research from Beko reveals the strangest items that are passed on [Yahoo! Finance]
4/18
09:44 am
azn
ICH Q9 (R1) Quality Risk Management (QRM) Training Course (ONLINE EVENT) [Yahoo! Finance]
Low
Report
ICH Q9 (R1) Quality Risk Management (QRM) Training Course (ONLINE EVENT) [Yahoo! Finance]
4/18
09:11 am
azn
Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency" [Yahoo! Finance]
Low
Report
Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency" [Yahoo! Finance]
4/16
01:19 pm
azn
Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer [Yahoo! Finance]
Low
Report
Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer [Yahoo! Finance]
4/16
01:00 pm
azn
AstraZeneca PLC (NASDAQ: AZN) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.
Low
Report
AstraZeneca PLC (NASDAQ: AZN) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.
4/16
10:14 am
azn
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research [Yahoo! Finance]
Low
Report
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research [Yahoo! Finance]
4/16
10:05 am
azn
Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]
Low
Report
Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]
4/16
09:54 am
azn
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB [Yahoo! Finance]
Low
Report
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB [Yahoo! Finance]
4/16
09:54 am
azn
Pharmaceutical Manufacturing Market to Surpass USD 2,301.6 Billion By 2032 | Generic Prescription Drugs to Remain at Top with Over 61% Contribution Says Astute Analytica [Yahoo! Finance]
Low
Report
Pharmaceutical Manufacturing Market to Surpass USD 2,301.6 Billion By 2032 | Generic Prescription Drugs to Remain at Top with Over 61% Contribution Says Astute Analytica [Yahoo! Finance]
4/16
08:32 am
azn
Saïd Dean On The Challenge Facing The World's Elite Business Schools [Yahoo! Finance]
Low
Report
Saïd Dean On The Challenge Facing The World's Elite Business Schools [Yahoo! Finance]
4/16
08:08 am
azn
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials [Yahoo! Finance]
Low
Report
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials [Yahoo! Finance]
4/16
08:00 am
azn
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
Low
Report
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
4/16
07:04 am
azn
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial [Yahoo! Finance]
Low
Report
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial [Yahoo! Finance]
4/16
07:00 am
azn
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
Low
Report
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
4/16
05:12 am
azn
The world may be entering a post-equity era, and the UK is the canary in the coalmine [Yahoo! Finance]
Low
Report
The world may be entering a post-equity era, and the UK is the canary in the coalmine [Yahoo! Finance]